Beta Bionics Q3 revenue $35.5M, lifts FY guidance; Mint cleared, 3D Intelligence 510(k) withdrawn for resubmission

Beta Bionics reported Q3 revenue of $35.5M (+30% YoY), raised FY revenue guidance to $124M-$126M, and announced FDA clearance for its Mint disposable pump. Net loss widened to $24.4M. The company withdrew its 3D Intelligence 510(k) to add simulator data, targeting resubmission in mid-Q4 2026.